Sofinnova Investments raises $500m for Fund XI

Sofinnova Investments, specializing in biopharma ventures, has successfully secured $500 million for its 11th flagship fund, marking the fundraise's presumed conclusion. The substantial amount reflects investor confidence in the potential of the biopharmaceutical sector. Sofinnova's expertise and track record likely played a pivotal role in attracting significant commitments for its latest fund. This achievement positions the firm strongly for future strategic investments in the dynamic biopharma landscape.